EGFR and non-small cell lung carcinoma: The updated results of the CHRYSALIS study found that following progression on platinum-based treatment, 114 patients with non-small cell lung cancer (NSCLC) with EGFR Exon 20 insertion mutations had a median OS of 23 months (95% CI 18.5–29.5).